Ozempic for prediabetes and insulin resistance: what the evidence shows

What did @urgirlmeggs actually say?

She documented her first semaglutide injection, disclosing a family history of diabetes and a personal diagnosis of prediabetes and insulin resistance. She confirmed starting at the standard 0.25mg dose, injected into abdominal fat, and followed the manufacturer's hold-for-six-seconds guidance. She expressed nerves about needles, wiped the site, let it air dry, and reported it felt like "a little pinch." No dramatic claims about weight loss or cures. Just someone doing the thing for the first time on camera.

What she said is actually pretty responsible by TikTok standards. She named her medical context, didn't hype outcomes, and showed real technique steps rather than skipping to before-and-after theatrics. That matters when 55,000 people are watching and some of them are probably about to do the same thing.

Does the science back this up?

Yes, mostly. Semaglutide is FDA-approved for type 2 diabetes (Ozempic) and chronic weight management (Wegovy), and the evidence for both indications is substantial. The SUSTAIN trial series and the STEP trials are the backbone here.

Her clinical profile, prediabetes plus insulin resistance, is exactly the population researchers are now studying for earlier GLP-1 intervention. The STEP 5 trial (Garvey et al., 2022, Nature Medicine) showed semaglutide 2.4mg produced sustained weight loss over 104 weeks in adults with obesity or overweight with at least one weight-related condition. More relevant to her situation, the SELECT trial (Lincoff et al., 2023, New England Journal of Medicine) found cardiovascular benefit in non-diabetic adults with overweight and established cardiovascular disease, suggesting the drug's effects extend beyond glycemic control.

For prediabetes specifically, a 2023 analysis in Diabetes Care found GLP-1 receptor agonists significantly reduced progression to type 2 diabetes compared to placebo. Starting early, when someone is insulin resistant but not yet diabetic, has a reasonable evidence basis. It is not fringe thinking.

What did they get wrong (or right)?

Largely right on the mechanics. Abdominal injection into subcutaneous fat is one of the three approved sites (abdomen, thigh, upper arm). Wiping with alcohol, letting it air dry before injecting, and holding the pen for several seconds after the click are all consistent with Novo Nordisk's prescribing information and standard nursing guidance.

The "six seconds" hold she mentioned is actually on the conservative end of correct. The prescribing information for Ozempic recommends holding for at least six seconds after the click to ensure full dose delivery. She got that right without apparently reading it off a card.

One small concern: she mentioned "I'm sure it's in the way" while adjusting the pen angle, suggesting some uncertainty about perpendicular placement. Subcutaneous injections should go in at a 90-degree angle for most people with adequate abdominal fat, which she appears to have. A shallow or angled injection risks incomplete delivery or subdermal placement. It's hard to confirm from the video, but worth flagging.

She did not make any cure claims, did not recommend a dose to viewers, and did not compare her medication to compounded alternatives. Credit where it's due.

What should you actually know?

If you are prediabetic or insulin resistant and considering semaglutide, the evidence does support its use, but context matters. Semaglutide is a prescription medication with real side effects. Nausea, vomiting, and gastrointestinal distress affect a meaningful percentage of users, particularly in the first weeks. The STEP trials reported GI adverse events in roughly 70-80% of participants at some point during treatment.

The starting dose of 0.25mg she described is the correct initiation dose for Ozempic, used for four weeks before any planned escalation. This is not a therapeutic dose for blood sugar or weight, it is a tolerability ramp. Viewers should not expect results at this dose and should not self-escalate.

Injection technique is not trivial. The FDA's MedWatch database includes reports of nodules, lipohypertrophy, and incomplete dosing linked to poor technique. Rotating injection sites and not reusing the same spot repeatedly matters over the long term.

Finally, prediabetes is a real condition that responds to lifestyle intervention. GLP-1 medications are one tool, not the only tool. The Diabetes Prevention Program (Knowler et al., 2002, New England Journal of Medicine) showed lifestyle changes reduced diabetes progression by 58% versus 31% for metformin. Medication and lifestyle are not mutually exclusive, but the drug should not replace the conversation about both.

Bottom line

This video is one of the more medically grounded first-injection posts you will find in the GLP-1 corner of TikTok. The creator named her diagnosis, confirmed her dose, used reasonable technique, and made zero outcome promises. The science behind her clinical indication is solid. The main gaps are around injection angle certainty and a lack of side effect preparation for her audience. Neither is a red flag, just an incomplete picture.